GCP
NUVB icon

GSA Capital Partners’s Nuvation Bio NUVB Stock Holding History

GSA Capital Partners’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.13M Buy
495,792
+481,681
+3,414% +$2.68M 0.13% 148
2025
Q4 		$126K Sell
14,111
-1,021,081
-99% -$6.32M 0.01% 1506
2025
Q3 		$3.83M Sell
1,035,192
-591,930
-36% -$1.61M 0.32% 8
2025
Q2 		$3.17M Buy
1,627,122
+966,070
+146% +$2.01M 0.22% 39
2025
Q1 		$1.16M Buy
661,052
+418,799
+173% +$953K 0.11% 271
2024
Q4 		$644K Buy
242,253
+167,321
+223% +$431K 0.05% 714
2024
Q3 		$172K Buy
+74,932
New +$229K 0.01% 1440
2024
Q1 		– Sell
-42,776
Closed -$65K – 1861
2023
Q4 		$65K Sell
42,776
-187,519
-81% -$241K 0.01% 1414
2023
Q3 		$309K Sell
230,295
-46,390
-17% -$77.2K 0.03% 1058
2023
Q2 		$498K Sell
276,685
-41,879
-13% -$71.2K 0.05% 739
2023
Q1 		$529K Buy
318,564
+71,023
+29% +$144K 0.05% 675
2022
Q4 		$475K Buy
247,541
+49,164
+25% +$99.5K 0.06% 631
2022
Q3 		$444K Buy
198,377
+163,635
+471% +$467K 0.06% 659
2022
Q2 		$113K Buy
+34,742
New +$152K 0.02% 1201

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

GSA Capital Partners's NUVB Position: Q1 2026 in Review

GSA Capital Partners increased its Nuvation Bio (NUVB) stake by 3,414% in Q1 2026, buying an estimated $2.68M and bringing the position to 495,792 shares worth $2.13M. The position accounts for 0.13% of the portfolio, ranked #148.

GSA Capital Partners first reported a position in NUVB in Q2 2022 and has held it in 14 quarters since. The position peaked at $3.83M in Q3 2025. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • GSA Capital Partners held 495,792 shares of Nuvation Bio worth $2.13M as of Q1 2026.
  • GSA Capital Partners bought 481,681 Nuvation Bio shares in Q1 2026, an estimated $2.68M.
  • Nuvation Bio made up 0.13% of GSA Capital Partners's portfolio in Q1 2026, its #148 holding.
  • GSA Capital Partners first reported a position in Nuvation Bio in Q2 2022 and has held it in 14 quarters since.
  • GSA Capital Partners's Nuvation Bio position peaked at $3.83M in Q3 2025.
  • 231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.